Organogenesis Holdings Inc. (NASDAQ:ORGO) Major Shareholder Sells $973,200.00 in Stock

Organogenesis Holdings Inc. (NASDAQ:ORGO) major shareholder Albert Erani sold 60,000 shares of the stock in a transaction on Friday, June 4th. The stock was sold at an average price of $16.22, for a total value of $973,200.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Albert Erani also recently made the following trade(s):

  • On Wednesday, June 9th, Albert Erani sold 150,000 shares of Organogenesis stock. The shares were sold at an average price of $15.31, for a total value of $2,296,500.00.
  • On Monday, June 7th, Albert Erani sold 94,612 shares of Organogenesis stock. The shares were sold at an average price of $16.14, for a total value of $1,527,037.68.

Shares of NASDAQ:ORGO opened at $14.92 on Friday. The company’s 50-day moving average is $19.24. Organogenesis Holdings Inc. has a 12-month low of $3.23 and a 12-month high of $24.34. The company has a market capitalization of $1.91 billion, a PE ratio of 41.45 and a beta of 1.84. The company has a quick ratio of 2.10, a current ratio of 2.50 and a debt-to-equity ratio of 0.40.

Organogenesis (NASDAQ:ORGO) last announced its quarterly earnings data on Monday, May 10th. The company reported $0.07 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.04) by $0.11. Organogenesis had a return on equity of 43.70% and a net margin of 11.66%. The firm had revenue of $102.55 million for the quarter, compared to analysts’ expectations of $86.30 million. As a group, research analysts expect that Organogenesis Holdings Inc. will post 0.33 EPS for the current fiscal year.

A number of research firms recently commented on ORGO. SVB Leerink reduced their target price on Organogenesis from $27.00 to $26.00 and set an “outperform” rating on the stock in a research note on Tuesday, May 11th. TheStreet cut Organogenesis from a “c” rating to a “d+” rating in a research note on Monday, May 10th. Credit Suisse Group increased their target price on Organogenesis from $9.00 to $21.00 and gave the company an “outperform” rating in a research note on Friday, March 12th. Finally, Zacks Investment Research cut Organogenesis from a “buy” rating to a “hold” rating in a research note on Saturday, May 8th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. Organogenesis has a consensus rating of “Buy” and an average target price of $18.80.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. New York Life Investments Alternatives bought a new stake in shares of Organogenesis in the fourth quarter worth about $936,000. JPMorgan Chase & Co. grew its stake in shares of Organogenesis by 317.5% in the fourth quarter. JPMorgan Chase & Co. now owns 62,726 shares of the company’s stock worth $472,000 after purchasing an additional 47,702 shares during the last quarter. EAM Investors LLC bought a new stake in shares of Organogenesis in the first quarter worth about $4,548,000. Wealth Dimensions Group Ltd. bought a new stake in shares of Organogenesis in the fourth quarter worth about $459,000. Finally, Cornerstone Investment Partners LLC bought a new stake in shares of Organogenesis in the first quarter worth about $293,000. 19.34% of the stock is currently owned by institutional investors.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic allograft wound covering and surgical barrier for application in the care of chronic and acute wounds or surgical implantation in spine, orthopedic, and sports medicine applications; Apligraf, a bioengineered bi-layered skin substitute for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft, a dermal substitute for the treatment of DFUs; NuShield, a dehydrated placental tissue wound covering and surgical barrier applied to the target tissue to support native healing; and PuraPly Antimicrobial, an antimicrobial barrier skin substitute to treat chronic and acute wounds.

Further Reading: Exchange-Traded Funds (ETFs)

Insider Buying and Selling by Quarter for Organogenesis (NASDAQ:ORGO)

Receive News & Ratings for Organogenesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organogenesis and related companies with MarketBeat.com's FREE daily email newsletter.